Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Share, Size, Trends, Industry Analysis Report, By Application (Infectious Disease, Immunological Disease, Cancer, Others) By Region; Segment Forecast, 2023 - 2032

Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Share, Size, Trends, Industry Analysis Report, By Application (Infectious Disease, Immunological Disease, Cancer, Others) By Region; Segment Forecast, 2023 - 2032

The Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market size is expected to reach USD 1,08,553.86 thousands by 2032, according to a new study by Polaris Market Research. The report “Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Share, Size, Trends, Industry Analysis Report, By Application (Infectious Disease, Immunological Disease, Cancer, Others) By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Global NHP pre-clinical studies are an essential step in the development of new drugs and vaccines, and CROs provide a cost-effective solution for conducting such studies. Recent advances in genomics and other technologies have improved our understanding of NHP biology and facilitated the use of NHPs in pre-clinical studies. However, the use of NHPs in research remains controversial, and there is a growing trend toward the development of alternative methods for pre-clinical testing that do not involve the use of animals.

Recent advances in genomics and other technologies have enabled a better understanding of NHP biology and improved the development of NHP models for translational research. These advances have also facilitated the use of NHPs in pre-clinical studies, allowing for a more comprehensive assessment of the safety and efficacy of new drugs and vaccines.

NHPs in pre-clinical studies at CROs in North America has become an essential step in drug development. The integration of new technologies and the upgradation of NHP models for translational research have improved the accuracy and efficacy of NHP pre-clinical studies.

While the use of NHPs in pre-clinical studies remains controversial due to ethical concerns, CROs adhere to strict ethical guidelines and regulations to ensure the welfare of animals used in research. Additionally, CROs work closely with regulatory agencies to ensure that the pre-clinical studies meet safety and efficacy requirements before advancing to clinical trials.

CROs in Europe follow strict ethical guidelines and regulations to ensure animal welfare and regulatory agencies oversee the safety and efficacy of pre-clinical studies. While the use of NHPs in pre-clinical studies remains controversial, these studies remain an essential step in drug development.

There is a growing trend towards the upgradation of NHP models for translational research, with more focus on using NHPs that have specific disease phenotypes. For example, NHP models of Alzheimer's disease, Parkinson's disease, and HIV infection have been developed to better understand the pathogenesis of these diseases and test new treatments.

However, the use of NHPs in pre-clinical studies remains controversial, and animal rights activists continue to voice their concerns about animal welfare. Many organizations have called for the development of alternative methods for pre-clinical testing that do not involve the use of animals.

Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market Report Highlights

The increasing interest in using non-human primate (NHP) based preclinical trials for research purposes has led to a significant boost in the growth of this segment.

North America witnesses the significant growth for the Non-Human Primate Pre-clinical studies at Contract Research Organizations periodically for the development and to identify cohorts of animals with specific phenotypes across centers.

The global players include ABL, Inc., Applied BioCode Corporation, BioLegend, Inc., Exocell, Inc., HUREL Corporation, iQ Biosciences, and Mabtech AB, among others.

Polaris Market Research has segmented the Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market report based on Application and Region:

Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market,

Application Outlook (Revenue, USD Thousands, 2019-2032)

Infectious Disease

Immunological Disease

Cancer

Cardiovascular Disease

Metabolic Diseases

Genetic Disease

Respiratory Diseases

Neurological Disease

Female Related Diseases

Others

Global Non-Human Primate Pre-clinical studies at Contract Research Organizations Market, Regional Outlook (Revenue - USD Thousands, 2019-2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa